Extracellular vesicles (CARMEV) for prevention of heart failure (continuation)
The overall goal is to develop extracellular vesicles (EVs) from bone marrow MSCs
to inhibit I/R injury after myocardial infarction (MI) -> heart failure prevention
Time period: 11/2021 – 11/2023
Lead: Karl-Henrik Grinnemo, Uppsala University Hospital
Involved partners: Uppsala University Hospital, Uppsala University, AstraZeneca.
EVs from BM-MSCs (patented technology) inhibit apoptosis of cardiomyocytes, stimulate angiogenesis and preserve the myocardial function including the extracellular matrix structure after ischemia-reperfusion injury in mice.
- dose-response assays, characterize the biologically active EV preparations
- confirm the safety of the EV product in animal experiments and human in vitro tests (biodistribution assays, complement activation assays, coagulation assay)
- generation of a final well-characterized EV product under GMP conditions.
- initiate contact with the Swedish MPA (Läkemedelsverket).